Understanding Polyendocrine Metabolic Ovarian Syndrome (PMOS) — Formerly Known as PCOS

What Is This Condition?

You may have heard of “polycystic ovary syndrome” or “PCOS.” This condition affects about 1 in 8 women and is one of the most common hormonal disorders in women of childbearing age. Despite its old name, it is not really about “cysts” on the ovaries. The small fluid-filled sacs seen on ultrasound are actually immature egg follicles — they are not true cysts and are not dangerous on their own.

Because the old name was confusing and misleading, an international team of doctors, researchers, and patients worked together to choose a new name that better describes what the condition actually is.

The New Name: Polyendocrine Metabolic Ovarian Syndrome (PMOS)

In 2026, after years of global surveys involving over 14,000 patients and health professionals, the condition was officially renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS for short.

Here is what each word in the new name means:

– Polyendocrine — “Poly” means many, and “endocrine” refers to hormones. This word captures the fact that the condition involves multiple hormonal imbalances, not just one.

– Metabolic — This reflects the strong connection to how the body processes sugar, fat, and energy. Many people with this condition have insulin resistance, meaning the body has trouble using insulin properly.

– Ovarian — The ovaries are still involved, but the new name removes the word “cysts” because the condition is not caused by cysts.

– Syndrome — This means it is a collection of related symptoms and health issues, not a single disease.

The old name “PCOS” will still be used alongside the new name during a transition period, so you may see both terms for a while.

Why Did the Name Change Matter?

The old name led many people — including some doctors — to think this was only a problem with the ovaries. In reality, it affects the whole body. The misleading name contributed to:

– Delayed diagnosis (up to 70% of people with the condition were going undiagnosed)

– Feelings of stigma and confusion

– Less research funding because it was seen as “just” a gynecological issue

– Fragmented care, with patients bouncing between specialists

The new name is designed to help patients, doctors, and researchers better understand and communicate about the true nature of this condition.

What Are the Symptoms?

PMOS can look different from person to person. Common signs and symptoms include:

– Irregular or missed periods — Cycles may be longer than 35 days, or periods may be absent for months at a time.

– Excess hair growth (hirsutism) — Unwanted hair on the face, chest, back, or abdomen due to higher-than-normal levels of male-type hormones (androgens).

– Acne and oily skin — Often on the face, chest, and upper back.

– Thinning hair — Hair loss on the scalp, similar to male-pattern baldness.

– Weight gain or difficulty losing weight — Especially around the midsection.

– Darkened skin patches — Particularly in skin folds like the neck, groin, or under the breasts.

– Difficulty getting pregnant — Due to irregular or absent ovulation.

Beyond these visible symptoms, PMOS is also linked to:

– Insulin resistance and type 2 diabetes

– High cholesterol and high blood pressure

– Sleep apnea

– Depression, anxiety, and reduced quality of life

– Increased risk of endometrial (uterine lining) cancer

– Pregnancy complications such as gestational diabetes and preeclampsia

How Is It Diagnosed?

A doctor will typically diagnose PMOS if at least two of the following three criteria are present (after ruling out other conditions):

1. Irregular ovulation — Shown by irregular or absent periods.
2. High androgen levels — Detected by blood tests or signs like excess hair growth and acne.
3. Polycystic-appearing ovaries — Seen on ultrasound, or detected by a blood test called anti-Müllerian hormone (AMH).

In teenagers, both irregular periods and signs of high androgens must be present for a diagnosis.

Your Immune System and PMOS: What You Should Know

One of the most important areas of new research involves the immune system — the body’s defense network. Scientists have discovered that the immune system plays a much bigger role in PMOS than previously thought. Here is what that means in plain language.

What Is “Low-Grade Chronic Inflammation”?

Normally, inflammation is a healthy response — it is how your body fights infections and heals injuries. But in PMOS, the body’s immune system is slightly “turned on” all the time, even when there is no infection. This is called chronic low-grade inflammation.

Think of it like a smoke alarm that keeps going off even when there is no fire. Over time, this constant low-level alarm causes wear and tear on the body.

What Goes Wrong With the Immune System?

In women with PMOS, researchers have found several immune system changes:

– More inflammatory immune cells — Certain white blood cells, including macrophages (cells that normally “eat” germs) and specific types of T cells (called Th17 cells), are more active and present in higher numbers.

– Fewer “peacekeeper” immune cells — Regulatory T cells (called Tregs), which normally calm the immune system down and prevent it from overreacting, are reduced.

– Higher levels of inflammatory chemicals — Substances like C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) are elevated in the blood. These are chemical messengers that promote inflammation.

– Lower levels of anti-inflammatory chemicals — Protective substances like IL-10 and TGF-β, which normally keep inflammation in check, are reduced.

This imbalance creates a vicious cycle: inflammation worsens insulin resistance, which increases androgen (male hormone) production, which in turn fuels more inflammation.

How Does This Affect the Ovaries?

The ovaries themselves show signs of this immune imbalance. Inflammatory cells and chemicals accumulate in ovarian tissue, which can:

– Interfere with the normal development and release of eggs (ovulation)

– Damage the cells surrounding the eggs (granulosa cells)

– Contribute to the formation of the small, immature follicles that give the ovaries their “polycystic” appearance on ultrasound

How Does This Affect Fertility and Pregnancy?

The immune changes in PMOS do not just affect ovulation — they also affect the uterine lining (endometrium), which is where a fertilized egg must implant to start a pregnancy.

Research has shown that in women with PMOS:

– The uterine lining may be less receptive to an embryo. The endometrium shows changes in how it responds to progesterone, a hormone critical for preparing the uterus for pregnancy. This is sometimes called “progesterone resistance.”

– Uterine natural killer (NK) cells are altered. These are specialized immune cells in the uterus that normally help with implantation and the development of blood vessels to nourish a pregnancy. In PMOS, uterine NK cells may be reduced in number and function, making it harder for an embryo to implant successfully.

– The inflammatory environment may increase miscarriage risk. Women with PMOS have higher levels of inflammatory chemicals in their blood during pregnancy, which may contribute to a higher risk of miscarriage and pregnancy complications like gestational diabetes and preeclampsia.

– Decidualization may be impaired. Decidualization is the process by which the uterine lining transforms to support a pregnancy. In some women with PMOS, this process does not happen properly, partly due to excess androgens and the inflammatory environment.

These findings help explain why some women with PMOS still have difficulty getting pregnant or maintaining a pregnancy even after ovulation has been restored with medication.

Does This Mean PMOS Is an Autoimmune Disease?

Not exactly. While PMOS shares some features with autoimmune conditions — such as chronic inflammation and immune cell imbalance — it is not classified as an autoimmune disease. However, some researchers believe the hormonal imbalances in PMOS may increase the risk of developing certain autoimmune conditions. This is an active area of research.

What Can Be Done?

While there is no cure for PMOS, many effective treatments can manage symptoms and reduce long-term health risks.

Lifestyle Changes (First-Line for Everyone)

– Regular physical activity — Aim for at least 150 minutes per week of moderate exercise. Any type of movement helps.

– Balanced eating — No single diet is proven to be best for PMOS. Focus on whole foods, fiber, lean proteins, and healthy fats. Reducing processed foods and added sugars can help with insulin resistance.

– Weight management — Even a modest weight loss of 5–10% of body weight can significantly improve symptoms, hormone levels, and fertility.

– Sleep and stress management — Poor sleep and chronic stress can worsen inflammation and hormonal imbalance.

Medications

– Birth control pills — Help regulate periods, reduce androgen levels, and protect the uterine lining. These are the first-line medication for menstrual irregularity and symptoms like acne and excess hair growth when pregnancy is not desired.

– Metformin — Helps the body use insulin more effectively. It is primarily recommended for metabolic features like insulin resistance and may also help with inflammation.

– Letrozole — The first-choice medication for helping with ovulation when trying to conceive.

– Spironolactone — Can help with excess hair growth and acne (must be used with contraception as it can affect a developing baby).

– Anti-obesity medications or bariatric surgery — May be considered in some cases based on individual circumstances.

Emerging Research on Immune-Targeted Treatments

Because of the growing understanding of the immune system’s role in PMOS, researchers are exploring new approaches:

– Anti-inflammatory strategies — Including antioxidants and lifestyle modifications that reduce chronic inflammation.

– Metformin’s immune benefits — Beyond its metabolic effects, metformin has been shown to help restore some of the immune cell changes seen in the endometrium of women with PMOS.

– Immunomodulatory therapies — Early research is exploring whether medications that calm the immune system could improve fertility outcomes in PMOS, though these are not yet standard treatments.

Emotional and Mental Health

Living with PMOS can be emotionally challenging. Depression, anxiety, eating disorders, and poor body image are more common in people with this condition. These are real medical concerns — not just reactions to symptoms — and may be partly driven by the same hormonal and inflammatory changes that cause other PMOS symptoms.

If you are struggling emotionally, please talk to your doctor. Screening for depression and anxiety is recommended for everyone with PMOS, and effective treatments are available.

Key Takeaways

– PMOS (formerly PCOS) is a whole-body condition involving hormones, metabolism, and the immune system — not just the ovaries.

– The new name, Polyendocrine Metabolic Ovarian Syndrome, better reflects what the condition truly is.

– Chronic low-grade inflammation and immune system imbalance play important roles in the condition, affecting everything from ovulation to the ability of the uterus to support a pregnancy.

– Lifestyle changes are the foundation of treatment, with medications available to target specific symptoms.

– Research into immune-targeted therapies is a promising and growing field.

– Mental health matters — screening and support should be part of every care plan.

 

References:

1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463
2. Teede HJ, Tay CT, Laven J, et al. Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction. 2023;38(9):1655-1679. doi:10.1093/humrep/dead156
3. Teede HJ, Khomami MB, Morman R, et al. Polyendocrine Metabolic Ovarian Syndrome, the New Name for Polycystic Ovary Syndrome: A Multistep Global Consensus Process. Lancet. 2026;S0140-6736(26)00717-8. doi:10.1016/S0140-6736(26)00717-8
4. Deng H, Chen Y, Xing J, Zhang N, Xu L. Systematic Low-Grade Chronic Inflammation and Intrinsic Mechanisms in Polycystic Ovary Syndrome. Frontiers in Immunology. 2024;15:1470283. doi:10.3389/fimmu.2024.1470283
5. Wang J, Yin T, Liu S. Dysregulation of Immune Response in PCOS Organ System. Frontiers in Immunology. 2023;14:1169232. doi:10.3389/fimmu.2023.1169232
6. Zhai Y, Pang Y. Systemic and Ovarian Inflammation in Women With Polycystic Ovary Syndrome. Journal of Reproductive Immunology. 2022;151:103628. doi:10.1016/j.jri.2022.103628
7. Jiang N, Liu J, Li C, et al. Natural Killer Cell Dysregulation in Polycystic Ovary Syndrome: Immunometabolic and Reproductive Implication. Frontiers in Immunology. 2026;17:1781451. doi:10.3389/fimmu.2026.1781451
8. Wegrzynowicz AK, Dudley CM, Cooney LG, Stanic AK. Maternal Complications of Pregnancy in Polycystic Ovary Syndrome. Reproduction. 2025;170(6):e250108. doi:10.1530/REP-25-0108
9. Palomba S, Piltonen TT, Giudice LC. Endometrial Function in Women With Polycystic Ovary Syndrome: A Comprehensive Review. Human Reproduction Update. 2021;27(3):584-618. doi:10.1093/humupd/dmaa051
10. Teede HJ, Tay CT, Laven J, et al. Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility. 2023;120(4):767-793. doi:10.1016/j.fertnstert.2023.07.025
11. Shabbir S, Khurram E, Moorthi VS, et al. The Interplay Between Androgens and the Immune Response in Polycystic Ovary Syndrome. Journal of Translational Medicine. 2023;21(1):259. doi:10.1186/s12967-023-04116-4
12. Piltonen TT, Chen JC, Khatun M, et al. Endometrial Stromal Fibroblasts From Women With Polycystic Ovary Syndrome Have Impaired Progesterone-Mediated Decidualization, Aberrant Cytokine Profiles and Promote Enhanced Immune Cell Migration in Vitro. Human Reproduction. 2015;30(5):1203-15. doi:10.1093/humrep/dev055
13. Stokkeland LMT, Giskeødegård GF, Ryssdal M, et al. Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism. 2022;107(1):39-52. doi:10.1210/clinem/dgab684
14. Eriksson G, Li C, Sparovec TG, et al. Single-Cell Profiling of the Human Endometrium in Polycystic Ovary Syndrome. Nature Medicine. 2025;31(6):1925-1938. doi:10.1038/s41591-025-03592-z
15. Zhang F, Wu J, Ge L, Huang Y, Huang Y. A Review of Immunometabolic Crosstalk in PCOS-related Pregnancy Loss: Mechanisms and Emerging Therapeutic Strategies. Gynecological Endocrinology. 2025;41(1):2600160. doi:10.1080/09513590.2025.2600160
16. De Robles G, Wiggins KD, Del Mundo Z, et al. Unpacking PCOS Inflammation: From Misconceptions to Immune Networks. Endocrinology. 2025;bqaf166. doi:10.1210/endocr/bqaf166